| Document |
Document Title |
|
JP2010527357T5 |
|
|
JP4703183B2 |
The present invention provides compounds which can modulate receptor kinase activity, particularly ephrin and EGFR, pharmaceutical compositions thereof and such compounds for use in treating cancer. The compounds comprise N-(3,4-dichloro...
|
|
JPWO2009101917A1 |
The compound represented by the formula (I) or a pharmaceutically acceptable salt thereof has an excellent sodium channel inhibitory effect and is useful as a therapeutic agent and analgesic for various neuralgias, neuropathy, epilepsy, ...
|
|
JP4694129B2 |
The present invention relates to 1-arylsulfonyl-3 substituted indole or indoline derivatives having the general formula (I) (I) wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R6-R11 are defined in the ...
|
|
JP2011105708A |
To provide a compound promoting the production of erythropoietin (EPO).There is provided a pharmaceutical composition containing the compound represented by general formula (1) or a pharmacologically acceptable salt thereof, specifically...
|
|
JP2011515435A |
This application discloses aminopiperidinyl compounds of generic Formulae I-II: or pharmaceutically acceptable salts thereof, wherein m, r, Q1, Q2, Q3, R, Ra, R1, R2a, R2b, and R3 are defined as described herein, useful for treatment of ...
|
|
JP2011098969A |
To provide a new type of a heterocyclic compound, and to provide an application method thereof.There is disclosed a compound having a substituted and unsaturated 5-, 6- or 7-membered heterocyclic ring having one or more nitrogen atoms or...
|
|
JP2011515435T |
An amino piperidinyl compound shown by general formula (I) and (II) with this application useful to disposal of a disease relevant to monoamine re-taking-in inhibitor, or its salt which can be permitted pharmacologically (the inside of a...
|
|
JP4685331B2 |
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated...
|
|
JP2011093929A |
To provide a new compound which is an androstane-type glucocorticoid receptor agonist.The compound is expressed by formula (I) (in the formula, X is O or S; R1 is 1-6C alkyl, 3-8C cycloalkyl, 3-8C cycloalkylmethyl, 3-8C cycloalkenyl or t...
|
|
JP2011079844A |
To provide a compound having receptor kinase activity especially one for modulating ephrin and EGFR, and a method of treating the receptor kinase activity-mediated disorder utilizing the compound and drug composition.This is a compound r...
|
|
JP2011511031A |
This invention relates to novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for the...
|
|
JP2011511030A |
This invention relates to novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for thera...
|
|
JP2011511005A |
2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in...
|
|
JP2011068690A |
To provide a solid pharmaceutical preparation for monoamine neurotransmitter re-uptake inhibitors which have a 2,3-disubstituted tropane structure, with high stability, rapid dissolving in-vitro and good bioavailability as well as high u...
|
|
JP4664564B2 |
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in ...
|
|
JP4636021B2 |
A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is -CH2, -CHF or -CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, ...
|
|
JP4628678B2 |
New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one ad...
|
|
JP2011503120A |
The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a the...
|
|
JP4619356B2 |
A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound o...
|
|
JP4616264B2 |
This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess ...
|
|
JP4616006B2 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I are suitable for use as herbicides.
|
|
JP4610480B2 |
The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic d...
|
|
JP4610333B2 |
The invention relates to a novel, technically applicable production method for preparing tropenol, optionally in the form of acid addition salts thereof.
|
|
JP2011500518A |
The present invention concerns a new molecule, I-124βCIT Iodine-124[2β-carbomethoxy-3β-(4-iodophenyl)-tropane] and its process of synthesis, for use in PET investigations.
|
|
JP2011500727A |
The present invention relates to Bicyclic Heterocycle Derivatives, compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metab...
|
|
JP2011500857A |
A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporte...
|
|
JP4607860B2 |
This invention relates to anti-androgenic N-[omega-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethy
l-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative p...
|
|
JP2010540493A |
The invention relates to a large-scale method for producing salts of (IR,5S) anhydroecgonine esters. The salt formation and selective crystallization of (IR,5S) anhydroecgonine esters with chiral acids is highly efficient in producing an...
|
|
JP4602903B2 |
4-substituted quinoline derivatives (I), their salts, solvates, hydrates and formulations are new. 4-substituted quinoline derivatives of formula (I), their salts, solvates, hydrates and formulations are new. [Image] A : oxygen, sulfur, ...
|
|
JP2010539075A |
This invention relates to novel phenoxazin-3-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical co...
|
|
JP2010539074A |
This invention relates to novel benzooxazol- and benzooxathiol-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and ...
|
|
JP4593559B2 |
The present invention concerns novel benzenesulphonamide compounds, defined by formula I. Therapeutic compositions comprising the benzenesulphonamide compounds of the invention or salts thereof and methods for producing the benzenesulpho...
|
|
JP2010536749A |
In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11beta-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions c...
|
|
JP4589006B2 |
Di(hetero)arylacetic acid (or tricyclic analog) quaternized tropanyl esters (I) are new. Also new are corresponding non-quaternized intermediates (IV). Quaternized tropanyl esters of formula (I), including their optical isomers, enantiom...
|
|
JP4584990B2 |
The invention claims compounds of the formula wherein is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18R19; R3 and R4 H, alkyl, hydroxyalkyl or -C(O)Oalkyl;...
|
|
JP4583761B2 |
The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the...
|
|
JP4574618B2 |
Compounds of Formula I: in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharm...
|
|
JP4568603B2 |
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A...
|
|
JP4571078B2 |
The present invention provides compounds of formula (I) wherein, X, Y, R<1>, R<2> and R<2> are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 recep...
|
|
JP2010532777A |
Compounds of formula (I) wherein the substituents have the meanings assigned to them in claim 1, are useful as pesticides.
|
|
JP2010229136A |
To provide a modulator of a chemokine receptor mechanism.The compound is expressed by formula (1), provided that, Z is expressed by formula (2).
|
|
JP4559703B2 |
The invention relates to a propellant-free inhalation formulation of tiotropium bromide or tiotropium bromide monohydrate, which is dissolved in water or in a mixture consisting of water and ethanol, and to propellant-free inhalable aero...
|
|
JP4560293B2 |
The invention relates to a process for preparing granisetron, or a pharmaceutically acceptable salt thereof, which comprises: a) cyclisation of a compound of formula (I) in an inert solvent and at a temperature between 0-100° C., in the...
|
|
JP4559086B2 |
New medicaments contain a quaternized 2,2-diphenylpropionic acid scopine ester anticholinergic agent (I) and a beta -mimetic agent (II). New medicaments contain: (a) a scopine derivative anticholinergic agent of formula (I); (b) at least...
|
|
JP2010215630A |
To provide compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher...
|
|
JP4554936B2 |
The invention relates to novel xanthene-carboxylic acid esters of general formula (1), in which X and the groups A, R, R1, R2, R3, R3', R4 and R4' are defined as per the claims and the description. The invention also relates to a method ...
|
|
JP4553902B2 |
The invention provides a novel crystalline anhydride of tiotropium bromide, a method for producing said anhydride and the use thereof for producing a medicament for the treatment of respiratory tract diseases, in particular, for the trea...
|
|
JP4550072B2 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
|
|
JP4550353B2 |
|
